{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:05:17Z","timestamp":1793210717854,"version":"4.5.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.jbspin.2016.10.008","type":"journal-article","created":{"date-parts":[[2016,12,7]],"date-time":"2016-12-07T15:16:57Z","timestamp":1481123817000},"page":"221-223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Febuxostat-associated eosinophilic polymyositis in marginal zone lymphoma"],"prefix":"10.1016","volume":"84","author":[{"given":"Georges","family":"Chahine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalil","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Ghorra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Khalife","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fouad","family":"Fayad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2016.10.008_bib0080","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMcp1001124","article-title":"Clinical practice","volume":"364","author":"Neogi","year":"2011","journal-title":"Gout. N Engl J Med"},{"key":"10.1016\/j.jbspin.2016.10.008_bib0085","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1093\/annonc\/mdv317","article-title":"FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk","volume":"26","author":"Spina","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jbspin.2016.10.008_bib0090","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1093\/rheumatology\/kep088","article-title":"Febuxostat: a new treatment for hyperuricaemia in gout","volume":"48","author":"Edwards","year":"2009","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.jbspin.2016.10.008_bib0095","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.rdc.2012.08.008","article-title":"Safety of urate-lowering therapies: managing the risks to gain the benefits","volume":"38","author":"Keenan","year":"2012","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.jbspin.2016.10.008_bib0100","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/jcpt.12322","article-title":"Febuxostat-associated drug reaction with eosinophilia and systemic symptoms (DRESS)","volume":"40","author":"Chou","year":"2015","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.jbspin.2016.10.008_bib0105","doi-asserted-by":"crossref","first-page":"107","DOI":"10.5694\/mja14.01404","article-title":"Febuxostat-associated rhabdomyolysis in chronic renal failure","volume":"203","author":"Ghosh","year":"2015","journal-title":"Med J Aust"},{"key":"10.1016\/j.jbspin.2016.10.008_bib0110","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/jcpt.12144","article-title":"Rhabdomyolysis associated with initiation of febuxostat therapy for hyperuricaemia in a patient with chronic kidney disease","volume":"39","author":"Kang","year":"2014","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.jbspin.2016.10.008_bib0115","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jbspin.2016.10.008_bib0120","article-title":"updated EULAR evidence-based recommendations for the management of gout","author":"Richette","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2016.10.008_bib0125","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2016.10.008_bib0130","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2016.10.008_bib0135","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/CRD.0b013e318229a908","article-title":"Allopurinol as a cardiovascular drug","volume":"19","author":"Kelkar","year":"2011","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.jbspin.2016.10.008_bib0140","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.3899\/jrheum.110092","article-title":"Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions","volume":"38","author":"Chohan","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2016.10.008_bib0145","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3899\/jrheum.111161","article-title":"Febuxostat hypersensitivity","volume":"39","author":"Abeles","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2016.10.008_bib0150","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2515\/therapie\/2013016","article-title":"Updating the French method for the causality assessment of adverse drug reactions","volume":"68","author":"Arimone","year":"2013","journal-title":"Therapie"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X16302019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X16302019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T04:53:28Z","timestamp":1536209608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X16302019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S1297319X16302019"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2016.10.008","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Febuxostat-associated eosinophilic polymyositis in marginal zone lymphoma","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2016.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}